ZYDUSLIFE — Zydus Lifesciences Income Statement
0.000.00%
Last trade - 00:00
- IN₹1.00tn
- IN₹1.01tn
- IN₹172.37bn
- 98
- 15
- 100
- 87
2019 March 31st | 2020 March 31st | R2021 March 31st | C2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 131,656 | 142,531 | 144,035 | 151,099 | 172,374 |
Cost of Revenue | |||||
Gross Profit | 78,606 | 87,452 | 89,608 | 88,614 | 101,811 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 107,834 | 125,151 | 118,730 | 125,231 | 149,888 |
Operating Profit | 23,822 | 17,380 | 25,305 | 25,868 | 22,486 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 23,821 | 14,954 | 23,992 | 28,381 | 25,897 |
Provision for Income Taxes | |||||
Net Income After Taxes | 18,518 | 11,756 | 22,056 | 23,264 | 20,019 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 18,488 | 11,766 | 21,336 | 44,873 | 19,603 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 18,488 | 11,766 | 21,336 | 44,873 | 19,603 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 18.1 | 14.4 | 23.4 | 21 | 23.8 |
Dividends per Share |